Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643401 | 0.75 | NPC1 (0.39) | AURKA | |
| SCHEMBL451027 | 0.72 | KDM4C (0.34) | KDM4CCDK5CDK5R1AURKAKDR | |
| SCHEMBL2411999 | 0.69 | NISCH (0.42) | TAAR1MTORADKNISCH | |
| SCHEMBL3481734 | 0.69 | — | — | |
| SCHEMBL3981088 | 0.67 | NISCH (0.54) | KDM4CCDK5CDK5R1TAAR1ADRA1D | |
| SCHEMBL559143 | 0.67 | MTOR (0.39) | CDK5CDK5R1TAAR1MTORADK | |
| SCHEMBL442421 | 0.66 | KDM4C (0.46) | KDM4CCDK5CDK5R1ADRA1DADRA1A | |
| SCHEMBL584984 | 0.66 | KDM4E (0.31) | — | |
| SCHEMBL1162842 | 0.65 | — | — | |
| SCHEMBL630634 | 0.65 | HDAC6 (0.41) | KDM4CCDK5CDK5R1AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023984-A1 | Compounds for the treatment of alzheimer's disease | BONNIE DAVIS | 2004-02-05 | — | — | US | disclosed |
| US-6569848-B1 | Analogs of galanthamine; cholinesterase inhibitors | Davis, Bonnie | 2003-05-27 | — | — | US | disclosed |
| US-6319919-B1 | INHIBITING ACETYL CHOLINESTERASE ACTIVITY | Davis, Bonnie | 2001-11-20 | — | — | US | disclosed |
| US-6268358-B1 | Compounds for the treatment of Alzheimer's disease | Davis, Bonnie | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023984-A1 | Compounds for the treatment of alzheimer's disease | GALC, PSEN1, ACHE | KDM4C 1710/4885CDK5 838/4885CDK5R1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.